Medically reviewed by Drugs.com. Last updated on May 6, 2021.
Generic name: teriflunomide 7mg
Dosage form: tablet, film coated
The recommended dose of AUBAGIO is 7 mg or 14 mg orally once daily. AUBAGIO can be taken with or without food.
Monitoring to Assess Safety
- Obtain transaminase and bilirubin levels within 6 months before initiation of AUBAGIO therapy. Monitor ALT levels at least monthly for six months after starting AUBAGIO [see Warnings and Precautions (5.1)].
- Obtain a complete blood cell count (CBC) within 6 months before the initiation of treatment with AUBAGIO. Further monitoring should be based on signs and symptoms of infection [see Warnings and Precautions (5.4)].
- Prior to initiating AUBAGIO, screen patients for latent tuberculosis infection with a tuberculin skin test or blood test for mycobacterium tuberculosis infection [see Warnings and Precautions (5.4)].
- Exclude pregnancy prior to initiation of treatment with AUBAGIO in females of reproductive potential [see Warnings and Precautions (5.2)].
- Check blood pressure before start of AUBAGIO treatment and periodically thereafter [see Warnings and Precautions (5.9)].
Frequently asked questions
- What are the new drugs used for multiple sclerosis (MS)?
- Can Aubagio cause PML as a side effect?
- Does Aubagio suppress the immune system?
- How long do Aubagio side effects last?
- Does Aubagio work in multiple sclerosis (MS)?
More about Aubagio (teriflunomide)
- Side Effects
- During Pregnancy or Breastfeeding
- Patient Tips
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 70 Reviews
- Generic Availability
- Drug class: selective immunosuppressants
- FDA Approval History
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.